Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
Recognition of Dr. Parag Mallick: Nautilus Biotechnology co-founder and Chief Scientist, Dr. Parag Mallick, received the 2024 Distinguished Investigator Award from the Academy for Radiology and Biomedical Imaging Research for his significant contributions to imaging research.
Nautilus Biotechnology's Mission: The company aims to revolutionize proteomics by developing a platform technology that enhances access to the proteome, ultimately advancing human health and medicine.
Trade with 70% Backtested Accuracy
Analyst Views on NAUT
No data
About NAUT
About the author
Nautilus (NAUT) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
Biotech Stocks Surge After Hours: Insider Purchases, Trial Progress, and Strategic Partnerships Drive Growth
Biotech Stocks Momentum: Several small-cap biotech stocks, including Nautilus Biotechnology and PepGen, are experiencing renewed investor interest due to insider buying, strategic partnerships, and clinical trial advancements, leading to notable after-hours gains.
Nautilus Biotechnology Highlights: Nautilus saw a significant rise in stock price following insider purchases by its CEO and a partnership with the Allen Institute, alongside a reported narrower loss and strong cash position.
Lixte Biotechnology's Financial Strategy: Lixte announced a $2.6 million investment in Bitcoin and Ethereum to diversify its treasury, reflecting a strategic shift aimed at enhancing flexibility in the digital economy.
RenovoRx and VolitionRx Developments: RenovoRx received positive feedback for its pancreatic cancer trial and is expanding commercialization efforts, while VolitionRx entered a partnership to advance its diagnostic technology for Antiphospholipid Syndrome.
Biotech Stocks Surge in After-Hours Trading Following Trial News, Insider Purchases, and Conference Excitement
Biotech Stock Movements: Several small- and mid-cap biotech stocks experienced significant gains in after-hours trading on September 9, 2025, driven by clinical updates, insider buying, and upcoming investor conferences, with notable performances from Immutep, Nautilus Biotechnology, and Pliant Therapeutics.
Immutep's Clinical Trial Update: Immutep's shares rose 4.37% after announcing that data from its Phase II trial for eftilagimod alpha will be presented at the CTOS 2025 conference, focusing on a rare cancer with high unmet need.
Nautilus Biotechnology Insider Buying: Nautilus Biotechnology's stock surged 12.25% following CEO Sujal M. Patel's significant insider purchases, indicating confidence in the company's future, alongside participation in an upcoming investor conference.
Kura Oncology's Regulatory Milestones: Kura Oncology's shares increased 6.12% after presenting at the H.C. Wainwright conference, highlighting key developments and upcoming regulatory milestones for its menin inhibitor targeting acute myeloid leukemia.
Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript
Earnings Call Overview: Nautilus Biotechnology held its Q2 2025 earnings call on July 31, 2025, where key participants included CEO Sujal Patel, CFO Anna Mowry, and Chief Scientist Parag Mallick.
Forward-Looking Statements: The company provided a reminder that statements made during the call are forward-looking and involve risks and uncertainties that could affect actual results, with additional details available in their press release.
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Company Announcement: Nautilus Biotechnology, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference with a fireside chat scheduled for June 10, 2025, at 2:00 p.m. Eastern Time, accessible via their website.
About Nautilus: The company is focused on developing a single-molecule protein analysis platform to enhance proteomics and improve access to proteome data, aiming to advance human health and medicine.
Nautilus (NAUT) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
Biotech Stocks Surge After Hours: Insider Purchases, Trial Progress, and Strategic Partnerships Drive Growth
Biotech Stocks Momentum: Several small-cap biotech stocks, including Nautilus Biotechnology and PepGen, are experiencing renewed investor interest due to insider buying, strategic partnerships, and clinical trial advancements, leading to notable after-hours gains.
Nautilus Biotechnology Highlights: Nautilus saw a significant rise in stock price following insider purchases by its CEO and a partnership with the Allen Institute, alongside a reported narrower loss and strong cash position.
Lixte Biotechnology's Financial Strategy: Lixte announced a $2.6 million investment in Bitcoin and Ethereum to diversify its treasury, reflecting a strategic shift aimed at enhancing flexibility in the digital economy.
RenovoRx and VolitionRx Developments: RenovoRx received positive feedback for its pancreatic cancer trial and is expanding commercialization efforts, while VolitionRx entered a partnership to advance its diagnostic technology for Antiphospholipid Syndrome.
Biotech Stocks Surge in After-Hours Trading Following Trial News, Insider Purchases, and Conference Excitement
Biotech Stock Movements: Several small- and mid-cap biotech stocks experienced significant gains in after-hours trading on September 9, 2025, driven by clinical updates, insider buying, and upcoming investor conferences, with notable performances from Immutep, Nautilus Biotechnology, and Pliant Therapeutics.
Immutep's Clinical Trial Update: Immutep's shares rose 4.37% after announcing that data from its Phase II trial for eftilagimod alpha will be presented at the CTOS 2025 conference, focusing on a rare cancer with high unmet need.
Nautilus Biotechnology Insider Buying: Nautilus Biotechnology's stock surged 12.25% following CEO Sujal M. Patel's significant insider purchases, indicating confidence in the company's future, alongside participation in an upcoming investor conference.
Kura Oncology's Regulatory Milestones: Kura Oncology's shares increased 6.12% after presenting at the H.C. Wainwright conference, highlighting key developments and upcoming regulatory milestones for its menin inhibitor targeting acute myeloid leukemia.
Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Conference Call Transcript
Earnings Call Overview: Nautilus Biotechnology held its Q2 2025 earnings call on July 31, 2025, where key participants included CEO Sujal Patel, CFO Anna Mowry, and Chief Scientist Parag Mallick.
Forward-Looking Statements: The company provided a reminder that statements made during the call are forward-looking and involve risks and uncertainties that could affect actual results, with additional details available in their press release.
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Company Announcement: Nautilus Biotechnology, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference with a fireside chat scheduled for June 10, 2025, at 2:00 p.m. Eastern Time, accessible via their website.
About Nautilus: The company is focused on developing a single-molecule protein analysis platform to enhance proteomics and improve access to proteome data, aiming to advance human health and medicine.
